July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Longitudinal progression of visual function metrics in early and intermediate age-related macular degeneration
Author Affiliations & Notes
  • Atalie C. Thompson
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Sandra Stinnett
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Ulrich F O Luhmann
    Roche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center, Basel, Switzerland
  • Vaishali Oza
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Lejla Vajzovic
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Anupama Horne
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Cynthia A Toth
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Scott W Cousins
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Eleonora M Lad
    Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Atalie Thompson, None; Sandra Stinnett, None; Ulrich Luhmann, Hoffman LaRoche (E); Vaishali Oza, None; Lejla Vajzovic, Alcon (F), Janssen Pharmaceutical (R), Knights Templar Eye Foundation (R), PDC's ENABLE award (R), Roche (F), Second Sight (F); Anupama Horne, None; Cynthia Toth, Alcon (P), Alcon (R), Genentech (F); Scott Cousins, Alimera Sciences (C), Eyedesis (C), Heidelberg Engineering (C), Maculogix (S), Stealth BioTherapeutics (R), Stealth BioTherapeutics (C), Theia Biosciences (S); Eleonora Lad, Hoffman La Roche (F)
  • Footnotes
    Support  NIH/NEI 1K23EY026988; The clinical study was funded by Hoffmann-La Roche through a research agreement with Duke University
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5546. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Atalie C. Thompson, Sandra Stinnett, Ulrich F O Luhmann, Vaishali Oza, Lejla Vajzovic, Anupama Horne, Cynthia A Toth, Scott W Cousins, Eleonora M Lad; Longitudinal progression of visual function metrics in early and intermediate age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5546.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to examine longitudinal changes in performance on psychophysical tests of visual function over 12 months in subjects with early and intermediate age-related macular degeneration (AMD).

Methods : Prospective cohort study of 101 subjects with AMD age-related eye disease study (AREDS) stage 2 (N=33), AREDS stage 3 (N=47), and age-matched, normal controls (N=21). At baseline, 6 and 12 months, subjects underwent a dilated retinal examination with best-corrected visual acuity (BCVA), mesopic microperimetry with eye tracking (MAIA), dark adaptometry (DA; AdaptDx), low luminance visual acuity (LLVA) testing (standard log 2.0 neutral density filter and computerized), and cone contrast test (CCT). Low luminance deficit (LLD) was calculated as the difference in letters read for BCVA and LLVA. Group comparisons were performed using two-sided significance tests.

Results : 82 subjects completed the 6-and 12-month follow-up visits. The drop-out rate (18.8%) in this aged population is a limitation of the 12 month analysis. However, the intermediate AMD group showed a statistically significant impairment in standard LLVA, standard LLD, and CCT red as compared to the normal group at 12 months (p<0.05). Microperimetry metrics (percent reduced threshold and average threshold), CCT green and blue, and rod intercept on DA remained significantly different between groups at 1 year, similar to the baseline visits (all p<0.05). At 12 months, standard calculated LLD became significantly greater among early (p=0.027) and intermediate (p=0.002) AMD compared to controls. The intermediate group lost the most ETDRS letters of standard BCVA, while the early group lost the least, resulting in a significant difference in BCVA change between the groups at 12 months (p=0.021). The intermediate AMD group also had a significant loss of retinal sensitivity on microperimetry average threshold relative to those with early AMD (p=0.001) or controls (p<0.001). The percent of intermediate patients with greater than 2 standard deviations plus the mean of normal values was significantly higher than in the normal group for both calculated LLD (p=0.022) and percent reduced threshold (p=0.017).

Conclusions : Our study suggests that calculated standard LLD and microperimetry average threshold may be useful functional measures of disease progression in eyes with early and intermediate AMD.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×